Founded in 1996 by interventional cardiologists John Simpson, PhD, MD, and Matthew Selmon, MD, LuMend Inc. develops and markets medical devices that enable physicians to cross Chronic Total Occlusions (CTO) in the coronary vasculature. These devices allow for the placement of conventional guide wires across target stenotic lesions, offering a cost-effective solution for treating blocked arteries.